New hope for stomach and bowel cancers: experimental drug Rina-S enters Mid-Stage trial
NCT ID NCT07539311
First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times
Summary
This Phase 2 trial is testing a new drug called Rina-S (rinatabart sesutecan) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The drug is given alone through an IV, and everyone receives it—no placebo. The study will check if the drug shrinks tumors and how long that effect lasts, while also monitoring side effects. Participants may continue treatment as long as their cancer does not worsen and side effects are manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rina-S (rinatabart sesutecan)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced gastrointestinal cancers that have not responded to other therapies.
- What could go wrong
- This is an early Phase 2 trial with a small number of participants, so results may not confirm effectiveness. Side effects are possible, and the drug may not work for all cancer types studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKōtoku, Tokyo-To, 135-8550, Japan
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
The University of Osaka Hospital
RECRUITINGSuita-shi, Osaka, 565-0871, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New platform aims to personalize cancer treatment for GI patients
- Could some GI cancer patients avoid major surgery? new study explores organ preservation
- Could silkworm pupas be the key to fighting muscle loss in cancer survivors?
- New hope for stomach cancer: experimental drug BHB810 enters human trials
- Tailored training may boost healthy living in GI cancer survivors
- New scanner could sharpen cancer radiation treatment